PolyPid Ltd., a late-stage biopharma company based in Israel, announced that it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in early 2026 for its product D-PLEX100, following positive topline results from its Phase 3 SHIELD II trial. The trial demonstrated a significant reduction in surgical site infections in patients undergoing abdominal colorectal surgery. The product has received Fast Track designation from the FDA, indicating an expedited review process. A Marketing Authorization Application $(MAA)$ for the European Union is expected to follow shortly after the NDA submission.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。